| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 113 | 65 |
| Net (decrease) increase in cash and cash equivalents | -3,348 | -3,131 |
| Cash and cash equivalents at beginning of period | 21,351 | - |
| Cash and cash equivalents at end of period | 18,003 | - |
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)